Advances on Canine and Feline Mammary Tumours

A special issue of Animals (ISSN 2076-2615). This special issue belongs to the section "Veterinary Clinical Studies".

Deadline for manuscript submissions: closed (31 January 2022) | Viewed by 5798

Special Issue Editors


E-Mail Website
Guest Editor
Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro (UTAD), 5000-801 Vila Real, Portugal
Interests: veterinary pathology; mammary oncobiology; canine mammary tumors

E-Mail Website
Guest Editor
Dept. Animal Medicine, Surgery and Pathology, Veterinary Medicine School, Complutense University of Madrid (UCM), 28040 - Madrid, Spain
Interests: canine mammary cancer, inflammatory mammary cancer, veterinary and comparative oncology, spontaneous animal models

E-Mail Website
Guest Editor
Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Padua, Italy
Interests: canine and feline mammary tumors, comparative oncology, extracellular vesicles

Special Issue Information

Dear Colleagues,

Spontaneous mammary gland tumors represent the most commonly diagnosed neoplasms in female dogs and constitute the third most frequent neoplasm in female cats. These naturally occurring tumors have been suggested as animal models for human breast cancer, due to similarities with their human counterpart in terms of etiopathogenesis, clinicopathological characteristics and biological behavior.

Although canine and feline mammary tumors have attracted considerable attention over the years, which is reflected on the escalating number of publications, further studies are warranted. In this Special Issue of Animals, we invite you to submit high-quality original research, reviews or reports focusing on canine and feline mammary tumors, including basic research, preclinical and clinical investigations.

We anticipate that this Special Issue will expand our current knowledge on canine and feline mammary tumors, advancing new information on several aspects in a joint effort of veterinary pathologists, oncologists and other researchers.

Prof. Adelina Gama
Prof. Laura Peña
Prof. Valentina Zappulli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Animals is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dog
  • cat
  • mammary tumors
  • veterinary pathology
  • oncology

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 3433 KiB  
Article
Serum Level of Tumor-Overexpressed AGR2 Is Significantly Associated with Unfavorable Prognosis of Canine Malignant Mammary Tumors
by Stephen Hsien-Chi Yuan, Shih-Chieh Chang, Yenlin Huang and Hao-Ping Liu
Animals 2021, 11(10), 2923; https://doi.org/10.3390/ani11102923 - 09 Oct 2021
Cited by 3 | Viewed by 1633
Abstract
Canine malignant mammary tumors (MMTs) are prevalent malignancy in intact female dogs with a high incidence of metastasis and recurrence. A current lack of easily accessible tumor biomarkers hinders a timely assessment of the disease outcome. We previously identified anterior gradient protein 2 [...] Read more.
Canine malignant mammary tumors (MMTs) are prevalent malignancy in intact female dogs with a high incidence of metastasis and recurrence. A current lack of easily accessible tumor biomarkers hinders a timely assessment of the disease outcome. We previously identified anterior gradient protein 2 (AGR2) with higher protein abundance in canine MMT tissues compared with normal counterparts. AGR2 is an endoplasmic reticulum-resident protein disulfide isomerase involved in the regulation of protein processing and also exists extracellularly via secretion to exert pro-oncogenic functions. In the present study, we validated overexpression of AGR2 in canine MMT tissues from 45 dogs using immunohistochemistry and immunoblotting, and assessed serum AGR2 levels in 81 dogs with MMTs and 21 benign cases using a competitive enzyme-linked immunosorbent assay (ELISA). Our data revealed that serum eAGR2 levels are significantly correlated with MMT progression (p = 0.0007) and remote tumor metastasis (p = 0.002). Moreover, elevated levels of serum eAGR2 are associated with an unfavorable overall survival of MMT dogs in later stage (p = 0.0158). Area under the time-dependent ROC curve (AUC) of serum eAGR2 level as a prognostic indicator was 0.839. Collectively, this study uncovered that serum eAGR2 level is significantly associated with an adverse outcome of MMT dogs and holds a predictive potential in MMT prognosis. Full article
(This article belongs to the Special Issue Advances on Canine and Feline Mammary Tumours)
Show Figures

Figure 1

13 pages, 4906 KiB  
Article
Establishment and Characterization of Feline Mammary Tumor Patient-Derived Xenograft Model
by Hsiao-Li Chuang, Yi-Chih Chang, Yi-Ting Huang, Jiunn-Wang Liao, Pei-Ling Kao, Yi-Fei Chen, Bin-Yin Lin, Yi-Lo Lin, Ter-Hsin Chen and Yu-Chih Wang
Animals 2021, 11(8), 2380; https://doi.org/10.3390/ani11082380 - 12 Aug 2021
Cited by 3 | Viewed by 2978
Abstract
Feline mammary tumor is a relatively commonly diagnosed neoplasm in the cat. Development of new veterinary cancer therapies is limited by the shortage of in vivo models that reproduce tumor microenvironment and metastatic progression. Four feline mammary tumor orthotopic patient-derived xenograft model (PDX) [...] Read more.
Feline mammary tumor is a relatively commonly diagnosed neoplasm in the cat. Development of new veterinary cancer therapies is limited by the shortage of in vivo models that reproduce tumor microenvironment and metastatic progression. Four feline mammary tumor orthotopic patient-derived xenograft model (PDX) successfully established in NOD-SCID gamma (NSG) mice. The overall success rate of PDX establishment was 36% (4/11). Histological, immunohistochemical, and short tandem repeat analysis showed a remarkable similarity between patient’s tumor and xenograft. The tumor grafts conserve original tumor essential features, including distant metastasis. Primary FMT-1807 cell line isolated from FMT-1807PDX tumor tissue. Tumorigenicity of FMT-1807 cells expanded from PDX was assessed by orthotopic injection into NSG mice. Mice yielded tumors which preserve the lung and liver metastasis ability. This work provides a platform for FMT translational investigation. Full article
(This article belongs to the Special Issue Advances on Canine and Feline Mammary Tumours)
Show Figures

Figure 1

Back to TopTop